Ardent Health Inc (ARDT) valuation
Ardent Health P/E ratio history
Ardent Health trades at 21.9 times its earnings over the last twelve months and 10.3 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $8.83 | $0.96 | 9.2 | 4.8 |
| Dec 31, 2024 | $17.08 | $1.58 | 10.8 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Ardent Health valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Ardent HealthARDT | $1.73B | 21.9 | 10.3 | 0.3 |
| AbsciABSI | $1.74B | — | — | — |
| Kestra Medical TechnologiesKMTS | $1.74B | — | — | 16.3 |
| Maze TherapeuticsMAZE | $1.74B | — | — | 87.1 |
| Intellia TherapeuticsNTLA | $1.74B | — | — | 29.3 |
| Butterfly NetworkBFLY | $1.70B | — | — | 13.8 |
| OmnicellOMCL | $1.67B | 43.6 | 17.1 | 1.3 |
| Nuvation BioNUVB | $1.66B | — | — | 9.8 |
| Zenas BiopharmaZBIO | $1.79B | — | — | — |
| Peer median | 43.6 | 17.1 | 15.1 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ARDT financials · ARDT returns
No forecast, no recommendation. This page describes Ardent Health Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.